国内外代谢相关脂肪性肝病管理指南中生活方式干预对比

摘要/Abstract

摘要： 代谢相关脂肪性肝病(MASLD)是全球最常见的慢性进展性肝病,估计患病率高达30%,且其发病率还在逐年上升,严重危害人类健康。截至目前,生活方式干预是管理MASLD的核心治疗手段,但不同指南在生活方式干预推荐意见上存在显著差异。本文纳入2020年亚太肝病研究学会、2021年美国胃肠病学会、2023年美国肝病研究学会、2024年欧洲肝病学会联合欧洲糖尿病学会和欧洲肥胖症学会,以及2024年中华医学会肝病学分会在内的5份MASLD防治指南,从减重、运动、饮食、饮酒和吸烟五方面进行总结和对比,旨在为MASLD生活方式干预的临床实践提供参考。

关键词: 代谢相关脂肪性肝病, 管理指南, 治疗和护理, 生活方式干预

刘爱芳, 罗磊, 杨文龙. 国内外代谢相关脂肪性肝病管理指南中生活方式干预对比[J]. 肝脏, 2025, 30(7): 1012-1016.

/ 推荐

参考文献

[1] Younossi Z M, Golabi P, Paik J M, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review[J]. Hepatology, 2023, 77(4): 1335-1347.
[2] Qi X, Li J, Caussy C, et al. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease[J]. Hepatology, 2024.
[3] Hagström H, Shang Y, Hegmar H, et al. Natural history and progression of metabolic dysfunction-associated steatotic liver disease[J]. Lancet Gastroenterol Hepatol, 2024, 9(10): 944-956.
[4] Keam S J. Resmetirom: first approval[J]. Drugs, 2024, 84(6): 729-735.
[5] Younossi Z M, Zelber-Sagi S, Henry L, et al. Lifestyle interventions in nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(11): 708-722.
[6] Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise[J]. J Hepatol, 2017, 67(4): 829-846.
[7] Eslam M, Sarin S K, Wong V W, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J]. Hepatol Int, 2020, 14(6): 889-919.
[8] Younossi Z M, Corey K E and Lim J K. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review[J]. Gastroenterology, 2021, 160(3): 912-918.
[9] Rinella M E, Neuschwander-Tetri B A, Siddiqui M S, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77(5): 1797-1835.
[10] EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. J Hepatol, 2024, 81(3): 492-542.
[11] 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 中华肝脏病杂志, 2024, 32(5): 418-434.
[12] Ivancovsky Wajcman D, Byrne C J, Dillon J F, et al. A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease[J]. Hepatology, 2024.
[13] Åberg F, Byrne C D, Pirola C J, et al. Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease[J]. J Hepatol, 2023, 78(1): 191-206.
[14] Kulkarni A V, Sarin S K. The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease[J]. Ther Adv Endocrinol Metab, 2023, 14: 20420188231178370.
[15] Andaloro S, Mancuso F, Miele L, et al. Effect of low-dose alcohol consumption on chronic liver disease[J]. Nutrients, 2024, 16(5):613.
[16] EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]. Diabetologia, 2016, 59(6): 1121-1140.
[17] Dunn W, Sanyal A J, Brunt E M, et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD)[J]. J Hepatol, 2012, 57(2): 384-391.
[18] Sookoian S, Castaáo G O, Pirola CJ. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals[J]. Gut, 2014, 63(3): 530-532.
[19] Magherman L, Van Parys R, Pauwels N S, et al. Meta-analysis: the impact of light-to-moderate alcohol consumption on progressive non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2023, 57(8): 820-836.
[20] Ajmera V, Belt P, Wilson L A, et al. Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis[J]. Clin Gastroenterol Hepatol, 2018, 16(9): 1511-1520.e5.
[21] Åberg F, Puukka P, Salomaa V, et al. Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts[J]. Hepatology, 2020, 71(3): 835-848.
[22] Premkumar M, Anand A C. Tobacco, cigarettes, and the liver: the smoking gun[J]. J Clin Exp Hepatol, 2021, 11(6): 700-712.
[23] McPherson S, Armstrong M J, Cobbold J F, et al. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group[J]. Lancet Gastroenterol Hepatol, 2022, 7(8): 755-769.
[24] Fan J G, Cao H X. Role of diet and nutritional management in non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol, 2013, 28(Suppl 4): 81-87.
[25] Malespin M H, Barritt A St, Watkins S E, et al. Weight loss and weight regain in usual clinical practice: results from the TARGET-NASH observational cohort[J]. Clin Gastroenterol Hepatol, 2022, 20(10): 2393-2395.e4.
[26] Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the american association for the study of liver diseases (AASLD)[J]. Endocr Pract, 2022, 28(5): 528-562.
[27] Muftah A A, Banala C, Raasikh T, et al. Telehealth interventions in patients with chronic liver diseases: a systematic review[J]. Hepatology, 2023, 78(1): 179-194.